Browse by Medical Category
Accepting New Patients
Dr. Brian Nahed is a neurosurgeon who specializes in Brain Tumors (Glioblastoma, Gliomas, Meningiomas, Metastatic Brain Tumors) and Spinal Disorders. He is an Assistant Professor in the Department of Neurosurgery and Pappas Center for Neurooncology. Please visit my web page.
Go To Programs
Go To Specialties
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Dr. Brian Nahed is a neurosurgeon specializing in brain tumors (glioblastoma, gliomas (low grade and high grade), metastatic brain tumors, and meningiomas) as well as Spinal Disorders. Dr. Nahed specializes in brain tumors of the eloquent cortex (language and motor areas of the brain) which require awake surgery, language and motor mapping, and subcortical stimulation. Born in New York, Dr. Nahed attended UCLA where he majored in Neuroscience, graduating Phi Beta Kappa and with the department's Highest Honors. He attended the Yale School of Medicine where he was awarded the Doris Duke Clinical Research Fellowship and graduated with honors. Dr. Nahed completed his internship and neurosurgery residency at the Massachusetts General Hospital; where Dr. Nahed also completed a postdoctoral fellowship with Drs. Daniel Haber and Shyamala Maheswaran in the MGH Cancer Center.Dr. Brian Nahed was recruited to the MGH Department of Neurosurgery and Brain Tumor Center in 2011. As an assistant professor of Harvard Medical School, Dr. Brian Nahed's research focuses on developing the first blood based test to diagnose and monitor brain tumors. In collaboration with Drs. Haber, Maheswaran, and Stott, Dr. Nahed recently published the first evidence of circulating tumor cells in the blood of patients with glioma. Dr. Nahed is actively enrolling patients into his translational clinical research study. Dr. Brian Nahed serves as the Associate Director of the MGH Neurosurgery Residency Program. He serves on the Executive Committee of the Congress of Neurological Surgeons and the CNS/AANS section on Tumors. He is an active member of the American Association of Neurological Surgeons and Council State Neurological Societies. Dr. Nahed is focused on education and socioeconomic issues in neurosurgery. He also serves as a neurotrauma consultant for the National Football League (NFL).
View my most recent research
Circulating Brain Tumor Cells and Blood Based Biomarkers for Brain Tumors
Dr. Brian Nahed's research recently identified the first evidence of tumor cells in the blood of patients with brain tumors - a landmark finding which changes our understanding of brain tumors and the blood. Dr. Brian Nahed and his colleagues developed the first device which they used to identify, capture, and analyze circulating tumor cells in the blood of patients with brain cancer. Through a collaboration between bioengineers, molecular biologists and clinicians, a circulating tumor cell capture device was developed to capture and detect tumor cells from patients with cancer. Under the mentorship of Drs. Daniel Haber, Shyamala Maheswaran, and Mehmet Toner, they aim to harness this technology to genetically characterize tumor cells without needing an invasive biopsy, and determine responsiveness to targeted cancer drugs. It also offers the opportunity to study cancer stem cells or metastasic precursors, thought to be at the origin of cancer spread via the bloodstream, to define their molecular vulnerabilities and help design new therapies to prevent cancer metastasis. Dr. Nahed has joined Dr. Shannon Stott to develop the first clinical tool to identify and monitor brain tumor patients using a blood test - expanding on their individual work on circulating tumor cells and exosomes.Dr. Nahed's research was recently published in Cancer Discovery and he is active enrolling patients in his translational clinical research study. More information about his research lab can found at the the Nahed Brain Tumor Research Lab.
View my most recent publications at PubMed
Dr. Brian Nahed has authored 107 publications in peer-reviewed journals and several book chapters and blogs.Please refer to pubmed for a complete list of the publications.Dr. Brian Nahed's research focuses on developing the first blood based clinical test to diagnose and monitor patients with brain tumors. More information about his research lab can be found at the Brian Nahed Brain Tumor Research Lab Website or at www.briannahed.com.
A Massachusetts General Hospital Neurosurgeon Works to Develop the First Blood-Based Test for Patients with Brain Tumors.
Confronted by criticism over its handling of player concussions, the NFL dramatically stepped up its response three years ago by installing neurotrauma specialists on the sidelines of every game and concussion spotters in booths high above the field.
Christine Zinke, 48, has had a difficult year. After being diagnosed in March with a meningioma brain tumor--a layer of tissue that covers the brain and spine--she underwent months of difficult treatment and therapy.
In the coming days, the sports world's focus will turn toward the NCAA tournament, but while the first two rounds of the big dance are always sure to surprise, the weekend's biggest Cinderella story might actually be taking place on an ice rink in West Chester, Pa.
Last Christmas, NYU goaltender Sam Daley received a one-of-a-kind gift from his parents, a custom goalie mask meant to illustrate all of the things that make Daley who he is: a native New Englander, a proud New Yorker, a strong family man and a hell of a hockey player.
The diagnosis came on New Year's Eve. NYU goaltender Sam Daley had a brain tumor. In the week since his family and teammates have come together to be #daleyStrong.
Sam Daley felt like something wasn’t right. Starting in October, Daley occasionally felt a tingling and numbness in his hand or on his left side.
The tingling sensation started around October 2014. It felt like Sam Daley's left ring and pinky fingers and the outside of his left foot would fall asleep randomly for 15 or 20 minutes every few days.
More than 70,000 patients will learn that they have a new primary brain tumor this coming year in the United States alone.6 While most of these patients will undergo surgery for removal and diagnosis, there are some for whom surgery is not a good option.5 Historically, treatment interventions for these individuals were more limited. Neurosurgeons frustrated by this limitation have been involved in the development and study of two new FDA-approved treatments. These are thermal therapy systems that sparked a renewed interest in Magnetic Resonance Guided Laser Induced Thermal Therapy (MRgLITT). LITT provides a minimally invasive surgical access coupled with the power of lasers to ablate a tumor from the inside out.
The recent Institute of Medicine (IOM) report heralding potentially major changes in the world of graduate medical education (GME) funding has brought the whole issue of residency training and its finances into the spotlight. One critical aspect of resident training – which resulted, in part, from an earlier IOM report – that is often overlooked is the unintended consequences on physician training resulting from work hour restrictions. Intended to protect residents and patients from fatigue-related medical errors and accidents, there is a growing recognition that these regulations are failing to serve their intended goals.
Back to Top